Prostate Cancer

acute leukemia treatment :: Article Creator Revumenib Earns FDA Priority Review In R/R KMT2Ar Acute Leukemia Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia. Priority review from the FDA has been granted to the new drug application (NDA) for revumenib in adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged acute leukemia. Findings from the AUGMENT-101 trial (NCT04065399) evaluating revumenib in adult and pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) support this decision. A Prescription Drug User Fee Act (PDUFA) target action date has been set for September 26, 2024. The FDA granted priority review to the NDA for revumenib in adult and pediatric R/R KMT2A-rearranged acute leukemia.1 Revumenib is a first-in-class Menin inhibitor. The NDA...

keytruda treatment :: Article Creator EU Approves Merck's Keytruda, Chemo Combo For Lung Cancer Pictured: Merck building and sign in Silicon Valley/iStock, Sundry Photography Merck announced Thursday that the European Commission has approved the use of its anti-PD-1 therapy Keytruda, in combination with platinum-containing chemotherapy, for resectable non-small cell lung cancer first as a neoadjuvant treatment and then continued as a monotherapy afterwards.  The therapy already has half a dozen indications in non-small cell lung cancer (NSCLC). The new expansion applies to resectable NSCLC at high risk of recurrence in adults. According to Merck, the EC's decision "marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for Keytruda in lung cancer in Europe."  Europe's regulator gave the green light following the resu...

best prostate cancer treatment centers 2020 :: Article Creator Questions To Ask Your Doctor About Metastatic Prostate Cancer A diagnosis of prostate cancer can stir up fear and worry. That's especially true when it's metastatic, or stage 4, prostate cancer, meaning that it has spread from the prostate to other parts of the body. "The diagnosis of metastatic prostate cancer, or any cancer for that matter, is emotionally debilitating," says Eleni Efstathiou, MD, PhD, a professor of medicine and chief of genitourinary medical oncology at Houston Methodist Neal Cancer Center in Texas. "We consider cancer to be the worst that can happen to us, and a lot of it has to do with stereotypes of older times where we didn't have [effective] treatments." Today, oncologists have many treatments to slow stage 4 prostate cancer. The more you know about your cancer and how your doctor will manage it, the less frightening it will se...

prostate cancer blood in stool :: Article Creator What Does It Mean When There Is Blood In Stool? Possible causes of blood in stool include gastroenteritis, anal fissures, hemorrhoids, inflammatory bowel disease, and more. Treatment can depend on the underlying cause. Below, learn more about the possible causes of bloody stool, including those more common in children. Also, find out how doctors diagnose and treat these issues. An injury to the gastrointestinal (GI) tract, inflammation, and ulcers can all cause the lining of the digestive tract to bleed. In some cases, perforation may occur, resulting in bleeding, abdominal pain, and severe illness. If bleeding occurs in the GI tract, the blood passes out of the body with the stool. Specific health issues that can lead to bleeding include the following: Gastroenteritis Gastroenteritis refers to viral, fungal, or parasitic infections that affect the stomach and intestines....

prostate cancer stage 7 life expectancy :: Article Creator Prostate Cancer News Jan. 23, 2024 — Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial has ... July 19, 2023 — Three new biomarkers for prostate cancer have been identified to help pinpoint potentially aggressive cases of the disease, which kills 300,000 men each ... July 12, 2023 — Prostate cancer is a leading cause of death among American men, and it's resistant to one of the most powerful chemotherapy medications -- cisplatin. Now, researchers have developed the first ... Apr. 10, 2023 — A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 ... Mar. 16, 2023 — The combination of two o...

palliative radiation therapy :: Article Creator Appropriate Radiation Therapy Not Given To Terminal Cancer Patients A considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation therapy despite spending most of their remaining life undergoing treatments, according to a new analysis. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer. Palliative radiotherapy for end-stage cancer patients is intended to control cancer-related pain and other symptoms and to help patients maintain a good quality of life when long-term cancer control is not possible. By reducing the number of cancer cells, palliative radiotherapy can ease pain, stop bleeding, and relieve pressure, even when the cancer cannot be controlled. However, for ma...